Episode 5

28 min

Nov 1, 2026

‘Immunosuppression for ALL patients with GVHD’ w. Robert Zeiser

‘Immunosuppression for ALL patients with GVHD’ w. Robert Zeiser

Prof. Robert Zeiser will discuss the traditional and evolving concepts behind graft-versus-host disease, and how understanding of this complex phenomenon after allogeneic transplantation may help reshape the treatment paradigm that exists for decades, namely immunosuppression.

Guest

Robert Zeiser

Robert Zeiser is Full Professor of Medicine and Director of the Division of Tumor Immunology at the Department of Hematology, Oncology, and Stem-Cell Transplantation at the Medical Center-University of Freiburg in Freiburg, Germany. Professor Zeiser’s laboratory research is focused on graft-versus-host disease, tumor biology, in vivo imaging, and signaling. He is Director of the Collaborative Research Center SFB 1479 at the University of Freiburg.

More episodes

  • Episode 4

    29 min

    Oct 4, 2026

    ‘CAR T cells CURE and CAUSE cancer’ w. Roni Shouval

    In this episode, together with Roni Shouval, we discuss the evolution of CAR T cells and their potential for cure: what does cure actually mean? We will also touch the hot topic of their potential for causing cancer, how likely it is and what this means for patients and clinicians alike.

    Roni Shouval

  • Episode 3

    27 min

    Sep 6, 2026

    ‘Conditioning intensity MATTERS for allogeneic transplant’ w. C. Craddock

    In this episode Prof. Charles Craddock discusses the major aims of conditioning regimens prior to allogeneic stem cell transplantation and how to select proper intensity of the regimen to balance Graft versus Leukemia effect and regimen related toxicity.

    Prof. Charles Craddock

  • Episode 2

    26 min

    Aug 9, 2026

    ‘MPN - does spleen size REALLY matter?’ w. Claire Harrison

    In this episode, Prof. Claire Harrison discusses the central role of the spleen in myelofibrosis - from its biology and clinical significance to its dominance as trial endpoint. The conversation explores how spleen responses relate to symptoms, survival, disease heterogeneity, and the future of endpoint selection in MPN clinical trials.

    Prof. Claire Harrison